<DOC>
	<DOCNO>NCT00627757</DOCNO>
	<brief_summary>The purpose study determine whether antipsychotic treatment influence psychiatric patient due endocrine metabolic status quality life . The investigator expect , 30-50 % patient show pharmacon - gene induce weight gain ( &gt; 7 % initial bodyweight ) rest patient maintain unaltered bodyweight .</brief_summary>
	<brief_title>Antipsychotic Medicine Metabolic Syndrome</brief_title>
	<detailed_description>The primary aim study investigate status neuro-and enteroendocrine ax focus beta - cell function relation insulin resistance , lipid profile abnormality inflammation adipokins patient treatment antipsychotic ( AP ) relation weight gain . The second aim evaluate connection weight gain patients´ perception quality life health .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>gender : male age : 1845 treatment minimum one Antipsychotic drug ( AP ) ethnicity : caucasian consent give take part project One criterion sufficient exclude patient study : compliance problem unable read , write talk Danish patient major lung , heart , lever kidney problem patient diagnose treatment Diabetes 1 2 patient take cholesterolreducing , weightreducing antihypertensive medication patient abuse alcohol drug patient duress § patient mentally ill 15 year patient diagnosis/treatment NIDDM/IDDM</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>metabolic syndrome</keyword>
	<keyword>weight gain</keyword>
	<keyword>antipsychotic drug</keyword>
	<keyword>Metabolic syndrome treatment antipsychotic drug</keyword>
</DOC>